Grilinctus-BM Syrup is a combination pharmaceutical formulation containing Terbutaline sulfate (2.5 mg per 5 ml) and Bromhexine hydrochloride (8 mg per 5 ml), designed for the management of respiratory conditions characterized by bronchospasm and excessive mucus production. Terbutaline, a selective beta-2 adrenergic receptor agonist, acts as a bronchodilator by relaxing the smooth muscles of the airways, thereby facilitating improved airflow and relief from bronchoconstriction. Bromhexine serves as a mucolytic agent, promoting the breakdown and clearance of viscous mucus from the respiratory tract, enhancing expectoration and reducing cough severity. This synergistic combination is particularly effective in treating obstructive airway diseases such as chronic bronchitis, asthma, and chronic obstructive pulmonary disease (COPD), where both airway constriction and mucus hypersecretion contribute to symptomatology. Grilinctus-BM Syrup is administered orally, with dosage tailored according to patient age, severity of symptoms, and clinical response. It is generally well-tolerated; however, caution is advised in patients with cardiovascular disorders, hyperthyroidism, or hypersensitivity to components. Adverse effects may include tremors, palpitations, gastrointestinal disturbances, or allergic reactions. Use under medical supervision is recommended to optimize therapeutic outcomes and monitor for potential side effects.